NeoRx has become the latest monoclonal antibody developer to benefitfrom the Food and Drug Administration's increased attention towardMoAb products. The Seattle company announced last week that theFDA has issued final approval for Verluma, a small-cell
NeoRx has become the latest monoclonal antibody developer to benefitfrom the Food and Drug Administration's increased attention towardMoAb products. The Seattle company announced last week that theFDA has issued final approval for Verluma, a small-cell lung cancerimaging agent (SCAN 12/27/95).
The FDA's action triggered a $4.5 million milestone paymentto NeoRx from Du Pont Merck Pharmaceutical, the product's NorthAmerican licensee. Boehringer Ingelheim affiliate Dr. Karl ThomaeGmbH is licensed to manufacture Verluma. The agent was formerlyknown as OncoTrac.
Verluma is composed of a monoclonal antibody Fab fragment linkedto a technetium-99m tracer. Verluma is indicated to determinethe stage of disease in a small-cell lung cancer patient, whichcan affect the course of therapy.
NeoRx is developing a cancer therapy agent, Avicidin, whichuses a different formulation of the Verluma antibody to home inon cancer sites. Avicidin is in phase I/II clinical trials.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.